The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches

Highlights Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The order is intended to support the Patch's planned commercial release.